What is MENS's health score?

Jyong Biotech Ltd. (MENS) has a TradeApes health score of 50 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is MENS's estimated fair value?

Based on our 5-year discounted cash flow model, Jyong Biotech Ltd.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is MENS undervalued or overvalued?

Our model currently rates MENS as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for MENS... Refresh in a moment for the full analysis.

Jyong Biotech Ltd. (MENS)

Healthcare Inconclusive inconclusive mixed

$2.1

Updated: 2026-06-05

TradeApes Score

Financial Strength

35 Weak

Operating Trend

55 Mixed

Relative Value

50 Mixed

Capital Allocation

45 Mixed

Risk

80 Strong

Key Findings

+ Net cash position — more cash on hand than total debt

Unlock Full Report →

− Weak interest coverage — earnings barely cover debt service

Unlock Full Report →

2 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.